Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression

Tsunehisa Kaku, Toshiharu Kamura, Toshio Hirakawa, Kunihiro Sakai, Satoshi Amada, Hiroaki Kobayashi, Hitoo Nakano

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective. To clarify the hypothesis that there are two pathways of endometrial carcinogenesis we compared the frequency of abnormal p53 protein expression and angiogenesis in endometrial carcinomas with and without hyperplasia. Methods. Specimens obtained from 70 patients with stage I-IV endometrial carcinomas were available for this immunohistochemical study. Immunohistochemical staining for factor VIII-related and p53 antigens was performed using a standard immunoperoxidase technique (Histofine SAB-PO Kit, Nichirei Co., Tokyo, Japan). Microvessels were highlighted by staining endothelial cells for factor VIII-related antigen, and microvessel density (MVD) was counted in a x200 field (0.785 mm2 per field) in the area of most active neovascularization, p53 protein was detected with monoclonal anti-p53 antibodies (clone DO-7, Dako, Santa Barbara, CA). Results. Twenty-six of 73 (37%) patients had hyperplasia in the endometrium adjacent to the carcinoma. Significantly more patients with low MVD (less than 60) had carcinoma with hyperplasia than those with carcinoma without hyperplasia (P = 0.0053). p53 expression was noted in a carcinomatous area in 8 of 26 patients (30.8%) with hyperplasia compared to 26 of 44 (59.1%) without hyperplasia, and the difference was statistically significant (P = 0.0220). Conclusion. The presence or absence of hyperplasia is a different pathogenesis and important in assessing the biological behavior of endometrial carcinoma, especially concerning angiogenesis and p53 expression.

Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalGynecologic Oncology
Volume72
Issue number1
DOIs
Publication statusPublished - Jan 1 1999

Fingerprint

Endometrial Neoplasms
Hyperplasia
Microvessels
von Willebrand Factor
Carcinoma
Staining and Labeling
Tumor Suppressor Protein p53
Tokyo
Endometrium
Immunoenzyme Techniques
Anti-Idiotypic Antibodies
Japan
Carcinogenesis
Proteins
Endothelial Cells
Clone Cells
Monoclonal Antibodies
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression. / Kaku, Tsunehisa; Kamura, Toshiharu; Hirakawa, Toshio; Sakai, Kunihiro; Amada, Satoshi; Kobayashi, Hiroaki; Nakano, Hitoo.

In: Gynecologic Oncology, Vol. 72, No. 1, 01.01.1999, p. 51-55.

Research output: Contribution to journalArticle

Kaku, T, Kamura, T, Hirakawa, T, Sakai, K, Amada, S, Kobayashi, H & Nakano, H 1999, 'Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression', Gynecologic Oncology, vol. 72, no. 1, pp. 51-55. https://doi.org/10.1006/gyno.1998.5230
Kaku, Tsunehisa ; Kamura, Toshiharu ; Hirakawa, Toshio ; Sakai, Kunihiro ; Amada, Satoshi ; Kobayashi, Hiroaki ; Nakano, Hitoo. / Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression. In: Gynecologic Oncology. 1999 ; Vol. 72, No. 1. pp. 51-55.
@article{ff1de33b84114f88b0164dfc7a82d57e,
title = "Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression",
abstract = "Objective. To clarify the hypothesis that there are two pathways of endometrial carcinogenesis we compared the frequency of abnormal p53 protein expression and angiogenesis in endometrial carcinomas with and without hyperplasia. Methods. Specimens obtained from 70 patients with stage I-IV endometrial carcinomas were available for this immunohistochemical study. Immunohistochemical staining for factor VIII-related and p53 antigens was performed using a standard immunoperoxidase technique (Histofine SAB-PO Kit, Nichirei Co., Tokyo, Japan). Microvessels were highlighted by staining endothelial cells for factor VIII-related antigen, and microvessel density (MVD) was counted in a x200 field (0.785 mm2 per field) in the area of most active neovascularization, p53 protein was detected with monoclonal anti-p53 antibodies (clone DO-7, Dako, Santa Barbara, CA). Results. Twenty-six of 73 (37{\%}) patients had hyperplasia in the endometrium adjacent to the carcinoma. Significantly more patients with low MVD (less than 60) had carcinoma with hyperplasia than those with carcinoma without hyperplasia (P = 0.0053). p53 expression was noted in a carcinomatous area in 8 of 26 patients (30.8{\%}) with hyperplasia compared to 26 of 44 (59.1{\%}) without hyperplasia, and the difference was statistically significant (P = 0.0220). Conclusion. The presence or absence of hyperplasia is a different pathogenesis and important in assessing the biological behavior of endometrial carcinoma, especially concerning angiogenesis and p53 expression.",
author = "Tsunehisa Kaku and Toshiharu Kamura and Toshio Hirakawa and Kunihiro Sakai and Satoshi Amada and Hiroaki Kobayashi and Hitoo Nakano",
year = "1999",
month = "1",
day = "1",
doi = "10.1006/gyno.1998.5230",
language = "English",
volume = "72",
pages = "51--55",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression

AU - Kaku, Tsunehisa

AU - Kamura, Toshiharu

AU - Hirakawa, Toshio

AU - Sakai, Kunihiro

AU - Amada, Satoshi

AU - Kobayashi, Hiroaki

AU - Nakano, Hitoo

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective. To clarify the hypothesis that there are two pathways of endometrial carcinogenesis we compared the frequency of abnormal p53 protein expression and angiogenesis in endometrial carcinomas with and without hyperplasia. Methods. Specimens obtained from 70 patients with stage I-IV endometrial carcinomas were available for this immunohistochemical study. Immunohistochemical staining for factor VIII-related and p53 antigens was performed using a standard immunoperoxidase technique (Histofine SAB-PO Kit, Nichirei Co., Tokyo, Japan). Microvessels were highlighted by staining endothelial cells for factor VIII-related antigen, and microvessel density (MVD) was counted in a x200 field (0.785 mm2 per field) in the area of most active neovascularization, p53 protein was detected with monoclonal anti-p53 antibodies (clone DO-7, Dako, Santa Barbara, CA). Results. Twenty-six of 73 (37%) patients had hyperplasia in the endometrium adjacent to the carcinoma. Significantly more patients with low MVD (less than 60) had carcinoma with hyperplasia than those with carcinoma without hyperplasia (P = 0.0053). p53 expression was noted in a carcinomatous area in 8 of 26 patients (30.8%) with hyperplasia compared to 26 of 44 (59.1%) without hyperplasia, and the difference was statistically significant (P = 0.0220). Conclusion. The presence or absence of hyperplasia is a different pathogenesis and important in assessing the biological behavior of endometrial carcinoma, especially concerning angiogenesis and p53 expression.

AB - Objective. To clarify the hypothesis that there are two pathways of endometrial carcinogenesis we compared the frequency of abnormal p53 protein expression and angiogenesis in endometrial carcinomas with and without hyperplasia. Methods. Specimens obtained from 70 patients with stage I-IV endometrial carcinomas were available for this immunohistochemical study. Immunohistochemical staining for factor VIII-related and p53 antigens was performed using a standard immunoperoxidase technique (Histofine SAB-PO Kit, Nichirei Co., Tokyo, Japan). Microvessels were highlighted by staining endothelial cells for factor VIII-related antigen, and microvessel density (MVD) was counted in a x200 field (0.785 mm2 per field) in the area of most active neovascularization, p53 protein was detected with monoclonal anti-p53 antibodies (clone DO-7, Dako, Santa Barbara, CA). Results. Twenty-six of 73 (37%) patients had hyperplasia in the endometrium adjacent to the carcinoma. Significantly more patients with low MVD (less than 60) had carcinoma with hyperplasia than those with carcinoma without hyperplasia (P = 0.0053). p53 expression was noted in a carcinomatous area in 8 of 26 patients (30.8%) with hyperplasia compared to 26 of 44 (59.1%) without hyperplasia, and the difference was statistically significant (P = 0.0220). Conclusion. The presence or absence of hyperplasia is a different pathogenesis and important in assessing the biological behavior of endometrial carcinoma, especially concerning angiogenesis and p53 expression.

UR - http://www.scopus.com/inward/record.url?scp=0032956565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032956565&partnerID=8YFLogxK

U2 - 10.1006/gyno.1998.5230

DO - 10.1006/gyno.1998.5230

M3 - Article

C2 - 9889029

AN - SCOPUS:0032956565

VL - 72

SP - 51

EP - 55

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -